• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加拿大两剂次麻疹免疫接种的效益成本分析。

A benefit-cost analysis of two-dose measles immunization in Canada.

作者信息

Pelletier L, Chung P, Duclos P, Manga P, Scott J

机构信息

Division of Immunization, Laboratory Centre for Disease Control (LCDC), Ottawa, Canada.

出版信息

Vaccine. 1998 May-Jun;16(9-10):989-96. doi: 10.1016/s0264-410x(97)00281-8.

DOI:10.1016/s0264-410x(97)00281-8
PMID:9682349
Abstract

In 1992, because of the limitations of the one-dose measles immunization program, the National Advisory Committee on Immunization (NACI) recommended a two-dose measles immunization program to eliminate measles. More recently, NACI recommended also a special catch-up program to prevent predicted measles outbreaks and to achieve an earlier elimination of measles. The objective of this study was to complete a benefit-cost analysis of a two-dose immunization program with and without a mass catch-up compaign compared with the current one-dose program. The resulting benefit: cost ratios vary between 2.61:1 and 4.31:1 depending on the strategy used and the age of the children targeted. Given the parameters established for this analysis, the benefits of a second-dose vaccination program against measles far outweight the costs of such a program under all scenarios.

摘要

1992年,由于单剂量麻疹免疫计划的局限性,国家免疫咨询委员会(NACI)建议采用两剂次麻疹免疫计划以消除麻疹。最近,NACI还建议开展一项特别的补种计划,以预防预计的麻疹疫情并更早地消除麻疹。本研究的目的是完成一项两剂次免疫计划的效益成本分析,该计划有无大规模补种活动,并与当前的单剂次计划进行比较。根据所采用的策略和目标儿童的年龄,所得的效益成本比在2.61:1至4.31:1之间。鉴于本次分析所设定的参数,在所有情况下,第二剂次麻疹疫苗接种计划的效益远远超过该计划的成本。

相似文献

1
A benefit-cost analysis of two-dose measles immunization in Canada.加拿大两剂次麻疹免疫接种的效益成本分析。
Vaccine. 1998 May-Jun;16(9-10):989-96. doi: 10.1016/s0264-410x(97)00281-8.
2
Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.2001 年韩国消除麻疹规划的经济学分析:成本效益分析研究。
Vaccine. 2013 May 31;31(24):2661-6. doi: 10.1016/j.vaccine.2013.04.014. Epub 2013 Apr 17.
3
Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.麻疹-腮腺炎-风疹疫苗与其他儿童常规疫苗同时接种。
Commun Dis Intell. 1998 Aug 6;22(8):159.
4
[Economic evaluation on different two-dose-vaccination-strategies related to Measles, Mumps and Rubella Combined Attenuated Live Vaccine].[麻疹、腮腺炎和风疹联合减毒活疫苗不同两剂次接种策略的经济学评价]
Zhonghua Liu Xing Bing Xue Za Zhi. 2016 Aug 10;37(8):1121-6. doi: 10.3760/cma.j.issn.0254-6450.2016.08.014.
5
The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.通过一项为期12年的两剂次疫苗接种计划,芬兰消除了本土麻疹、腮腺炎和风疹。
N Engl J Med. 1994 Nov 24;331(21):1397-402. doi: 10.1056/NEJM199411243312101.
6
Catch-up immunization programs will eliminate measles threat for most schoolchildren.补种免疫计划将消除大多数学童面临的麻疹威胁。
CMAJ. 1996 May 15;154(10):1567-8.
7
Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP).麻疹、腮腺炎和风疹——疫苗使用及消除麻疹、风疹和先天性风疹综合征并控制腮腺炎的策略:免疫实践咨询委员会(ACIP)的建议
MMWR Recomm Rep. 1998 May 22;47(RR-8):1-57.
8
Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).预防麻疹、风疹、先天性风疹综合征和流行性腮腺炎,2013 年:免疫实践咨询委员会(ACIP)的总结建议。
MMWR Recomm Rep. 2013 Jun 14;62(RR-04):1-34.
9
Benefits, risks and costs of immunization for measles, mumps and rubella.麻疹、腮腺炎和风疹免疫接种的益处、风险及成本
Am J Public Health. 1985 Jul;75(7):739-44. doi: 10.2105/ajph.75.7.739.
10
A second dose of MMR vaccine for children in the United Kingdom.英国儿童的第二剂麻疹、腮腺炎和风疹(MMR)疫苗
Commun Dis Rep CDR Wkly. 1996 Jul 26;6(30):259.

引用本文的文献

1
Global trends in measles publications.麻疹相关出版物的全球趋势。
Pan Afr Med J. 2020 Feb 20;35(Suppl 1):14. doi: 10.11604/pamj.supp.2020.35.1.18508. eCollection 2020.
2
Economic burden and associated factors of measles patients in Zhejiang Province, China.中国浙江省麻疹患者的经济负担及相关因素。
Hum Vaccin Immunother. 2019;15(11):2571-2577. doi: 10.1080/21645515.2019.1599673. Epub 2019 Apr 22.
3
Measles vaccination in an increasingly immunized and developed world.在一个免疫水平不断提高、日益发达的世界中开展麻疹疫苗接种。
Hum Vaccin Immunother. 2019;15(1):28-33. doi: 10.1080/21645515.2018.1517074. Epub 2018 Sep 19.
4
Economic evaluations of vaccines in Canada: a scoping review.加拿大疫苗的经济评估:一项范围综述。
Cost Eff Resour Alloc. 2017 May 5;15:7. doi: 10.1186/s12962-017-0069-4. eCollection 2017.
5
Health economics of rubella: a systematic review to assess the value of rubella vaccination.风疹的健康经济学:系统评价评估风疹疫苗接种的价值。
BMC Public Health. 2013 Apr 29;13:406. doi: 10.1186/1471-2458-13-406.
6
The economic disease burden of measles in Japan and a benefit cost analysis of vaccination, a retrospective study.日本麻疹的经济疾病负担和疫苗接种的效益成本分析:一项回顾性研究。
BMC Health Serv Res. 2011 Oct 7;11:254. doi: 10.1186/1472-6963-11-254.
7
Another look at the human papillomavirus vaccine experience in Canada.再看加拿大的人乳头瘤病毒疫苗接种经验。
Am J Public Health. 2011 Oct;101(10):1850-7. doi: 10.2105/AJPH.2011.300205. Epub 2011 Aug 18.
8
Net cost of palivizumab for respiratory syncytial virus prophylaxis during the 1998/99 season in northern Alberta.1998/99年冬季,在阿尔伯塔省北部使用帕利珠单抗预防呼吸道合胞病毒的净成本。
Paediatr Child Health. 2001 Oct;6(8):525-32. doi: 10.1093/pch/6.8.525.
9
Knowledge synthesis of benefits and adverse effects of measles vaccination: the Lasbela balance sheet.麻疹疫苗接种的益处与不良反应的知识综合:拉斯贝拉资产负债表
BMC Int Health Hum Rights. 2009 Oct 14;9 Suppl 1(Suppl 1):S6. doi: 10.1186/1472-698X-9-S1-S6.
10
Health burden and economic impact of measles-related hospitalizations in Italy in 2002-2003.2002 - 2003年意大利麻疹相关住院病例的健康负担及经济影响
BMC Public Health. 2007 Jul 24;7:169. doi: 10.1186/1471-2458-7-169.